摘要
目的:分析乳腺癌不同组织学类型及分级在新辅助化疗疗效预测中的价值。方法:细针穿刺活检确诊的53例乳腺癌病例,给予蒽环类新辅助化疗2周期,化疗前明确组织学类型、分级等临床病理特征,化疗后行乳腺改良根治术并行术后病理检测,评估化疗疗效,分析各临床病理特征与化疗疗效的关系。结果:53例乳腺癌患者新辅助化疗后,病理缓解(包括部分及完全缓解)41例(77.4%),其中病理完全缓解3例(5.7%)。新辅助化疗疗效与组织学类型及分级密切相关(P<0.01),与年龄、是否绝经及原发肿瘤期别均无关(P>0.05)。结论:新辅助化疗疗效仅与组织学类型及分级相关,浸润性导管癌化疗的疗效较非浸润性导管癌疗效佳。组织学分级高者优于分级低者,组织学亚型及级别可作为新辅助化疗敏感病例选择的预测因子。
Objective： To study the role of tumor histology and grading as the predictive factor for the effect of neo- adjuvant chemotherapy in breast cancer. Methods： All 53 cases of breast cancer confirmed by core biopsy received neoadjuvant chemotherapy with anthraeycline for two cycles,which were followed by masteetomy. Pathologic response rates were measured after mastectomy. It was analysed statistically that the correlation between cliniclpathology charac- ters and the response rate to neoadjuvant chemotherapy. Results：Among all the 53 cases, neoadjuvant chemotherapy achieved clinical response in 77.4% of patients and complete pathologic response in 5.7%. Tumor histology and grade were significant independent prognostic factors but age, menopause, prime tumour grading, tumor histology and grade were not related with prognosis. Conclusion：The response rate to chemotherapy was more significant in patiants with invasive ductal carcinoma of breast than non - invasive ductal carcinoma, with high - grade than low - grade. The study suggested that tumor histology and grading could be playing significant roles in the selection and management of patients with breast cancer for neoadjuvant chemotherapy.
出处
《现代肿瘤医学》
CAS
2013年第1期78-80,共3页
Journal of Modern Oncology
基金
陕西省卫生科研基金项目(编号:2010C12)
